AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28688129 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg plus ribavirin for 16 weeks
Number of subjects: 73
Study 28688129 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg plus ribavirin for 16 weeks (C‐CREST Part C)
Number of subjects: 73
Study 26725391 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lifestyle intervention for 22 weeks
Number of subjects: 109
Study 26725391 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 109
Study 23008337 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers for treatment (n = 161)
Number of subjects: 443
Study 23008337 — intervention group
Group type: COMPARATOR
Intervention: Nonvolunteers for treatment (n = 443)
Number of subjects: 443
Study 23008337 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmatched volunteers
Number of subjects: 443
Study 23008337 — intervention group
Group type: COMPARATOR
Intervention: Unmatched nonvolunteers
Number of subjects: 443
Study 21496511 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐DBT (multimedia e‐Learning course)
Number of subjects: 132
Study 21496511 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual (Linehan's Skills Training Manual for Borderline Personality Disorder)
Number of subjects: 132
Study 21496511 — intervention group
Group type: COMPARATOR
Intervention: e‐Control (placebo control e‐Learning course)
Number of subjects: 132
Study 21496511 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐DBT
Number of subjects: 132
Study 18451321 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mmol/day of oral sodium supplements (normal sodium intake)
Number of subjects: 220
Study 18451321 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (low sodium intake)
Number of subjects: 220
Study 18451321 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 220
Study 16585019 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6 mg) on day 4 or 8 of each cycle
Number of subjects: 41
Study 12927004 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 4611
Study 12927004 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 4611
Study 11044005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral predictive thermometer
Number of subjects: 500
Study 11044005 — intervention group
Group type: EXPERIMENTAL
Intervention: IRED tympanic thermometer
Number of subjects: 500
Study 11044005 — intervention group
Group type: COMPARATOR
Intervention: Oral glass mercury thermometer
Number of subjects: 500
Study 8867395 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (hormonal replacement therapy)
Number of subjects: 93
Study 8867395 — intervention group
Group type: COMPARATOR
Intervention: Non-HRT (no hormone regimen)
Number of subjects: 93
Study 8867395 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 93
Study 8867395 — intervention group
Group type: COMPARATOR
Intervention: Non-HRT
Number of subjects: 93
Study 1611373 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical standard set by general practitioner trainers for recurrent wheezy chest
Number of subjects: 9000
Study 1611373 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no standard setting)
Number of subjects: 9000
Study 6734056 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg quazepam tablet at night just before sleep
Number of subjects: 12
Study 6734056 — intervention group
Group type: COMPARATOR
Intervention: 15-mg quazepam tablet in the morning after a night's sleep
Number of subjects: 12
Study 3026039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-gluconate (1.58 g Ca)
Number of subjects: 13
Study 3026039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossopan (osseino-mineral complex, 1.58 g Ca)
Number of subjects: 13
Study 3026039 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 24-hour urine excretion
Number of subjects: 13
Study 31965527 — intervention group
Group type: EXPERIMENTAL
Intervention: Black physician
Number of subjects: 238
Study 31965527 — intervention group
Group type: COMPARATOR
Intervention: White physician
Number of subjects: 238
Study 29055155 — intervention group
Group type: EXPERIMENTAL
Intervention: apremilast 30 mg bid
Number of subjects: 100
Study 29055155 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 26645588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen (50-400 mg, administered subcutaneously or via a 2-h intravenous infusion)
Number of subjects: 87
Study 26645588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen (200 mg IV)
Number of subjects: 87
Study 26645588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 26645588 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg IV)
Number of subjects: 87
Study 24255061 — intervention group
Group type: EXPERIMENTAL
Intervention: evolocumab+SOC
Number of subjects: 1104
Study 24255061 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 1104
Study 22894911 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil diet enriched with α-linolenic acid (ALA) (3.5 g/d)
Number of subjects: 81
Study 22894911 — intervention group
Group type: COMPARATOR
Intervention: Olive oil diet rich in MUFA but low in ALA
Number of subjects: 81
Study 20838622 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folic acid (0.8 mg/d), vitamin B12 (0.5 mg/d), and vitamin B6 (20 mg/d) for 24 months
Number of subjects: 271
Study 20838622 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 271
Study 20838622 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose B vitamins
Number of subjects: 271
Study 18929098 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models for glaucoma development
Number of subjects: 0
Study 18929098 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive models for glaucoma progression
Number of subjects: 0
Study 18929098 — intervention group
Group type: EXPERIMENTAL
Intervention: Current models for assessing risk of glaucoma development
Number of subjects: 0
Study 18929098 — intervention group
Group type: EXPERIMENTAL
Intervention: Limitations of predictive models
Number of subjects: 0
Study 16024212 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) group
Number of subjects: 120
Study 16024212 — intervention group
Group type: COMPARATOR
Intervention: No Decision Aid (NDA) group
Number of subjects: 120
Study 16024212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 12842237 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 to 20 mg)
Number of subjects: 29
Study 12842237 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (Control)
Number of subjects: 29
Study 10375147 — intervention group
Group type: EXPERIMENTAL
Intervention: Representative payeeship
Number of subjects: 54
Study 8876922 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person progress reports from perioperative nurses
Number of subjects: 200
Study 8876922 — intervention group
Group type: COMPARATOR
Intervention: Attention protocol (checklist explaining hospital routines, waiting room procedures)
Number of subjects: 200
Study 8876922 — intervention group
Group type: COMPARATOR
Intervention: Telephone progress reports
Number of subjects: 200
Study 8876922 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative care (control group)
Number of subjects: 200
Study 2060564 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 12 mg.kg‐1.day‐1
Number of subjects: 9
Study 2060564 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 4.2 mg.kg‐1.day‐1
Number of subjects: 9
Study 2060564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6140018 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 0
Study 6140018 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 0
Study 6140018 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 0
Study 6140018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30368796 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of honey
Number of subjects: 30
Study 30368796 — intervention group
Group type: COMPARATOR
Intervention: 15 g of marmalade (Control)
Number of subjects: 30
Study 30368796 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey vs Glucose solution
Number of subjects: 30
Study 30390827 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind condition (ride on feel)
Number of subjects: 0
Study 30390827 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative condition (focusing on skills for efficient cycling)
Number of subjects: 0
Study 30390827 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociative condition (focusing concentration elsewhere)
Number of subjects: 0
Study 30390827 — intervention group
Group type: EXPERIMENTAL
Intervention: Full feedback condition (pace regulated via observation)
Number of subjects: 0
Study 27184093 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative bronchial genomic classifier result (low risk)
Number of subjects: 36
Study 27184093 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive bronchial genomic classifier result (intermediate risk)
Number of subjects: 36
Study 27184093 — intervention group
Group type: EXPERIMENTAL
Intervention: Classifier results reported for patients with benign disease
Number of subjects: 36
Study 27184093 — intervention group
Group type: EXPERIMENTAL
Intervention: Classifier results reported for patients with malignant disease
Number of subjects: 36
Study 24438173 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 °C trial
Number of subjects: 10
Study 24438173 — intervention group
Group type: COMPARATOR
Intervention: 38 °C trial
Number of subjects: 10
Study 24438173 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trials
Number of subjects: 10
Study 22430269 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC) integrated with standard oncology care
Number of subjects: 151
Study 22430269 — intervention group
Group type: COMPARATOR
Intervention: Standard oncology care alone
Number of subjects: 151
Study 20075644 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-mg ER hydromorphone
Number of subjects: 0
Study 20075644 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-mg ER hydromorphone
Number of subjects: 0
Study 20075644 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-mg ER hydromorphone
Number of subjects: 0
Study 20075644 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg IR hydromorphone
Number of subjects: 0
Study 20075644 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mg ER hydromorphone (milled)
Number of subjects: 0
Study 20075644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18940481 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-reduction and rigid internal fixation (ORIF)
Number of subjects: 142
Study 18940481 — intervention group
Group type: COMPARATOR
Intervention: Maxillomandibular fixation (MMF)
Number of subjects: 142
Study 16091635 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day)
Number of subjects: 64
Study 16091635 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 64
Study 16091635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 11685061 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular blood flow tonometer (OBF)
Number of subjects: 69
Study 11685061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonopen
Number of subjects: 69
Study 11685061 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 69
Study 9716159 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg rHDL/kg body weight
Number of subjects: 0
Study 9716159 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rHDL/kg body weight
Number of subjects: 0
Study 9716159 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro rHDL
Number of subjects: 0
Study 7990026 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allograft (DFDBA) with barrier material
Number of subjects: 36
Study 7990026 — intervention group
Group type: COMPARATOR
Intervention: No DFDBA (control)
Number of subjects: 36
Study 2917591 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 30 mg t.d.s. for 3 days
Number of subjects: 0
Study 2917591 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg after diltiazem pretreatment
Number of subjects: 0
Study 2917591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 956002 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow speaking rate (90 words/min)
Number of subjects: 24
Study 956002 — intervention group
Group type: COMPARATOR
Intervention: Normal speaking rate (140 words/min)
Number of subjects: 24
Study 31033774 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg knee-extensor (KE)
Number of subjects: 10
Study 31033774 — intervention group
Group type: COMPARATOR
Intervention: Single-leg cycle ergometry (CE)
Number of subjects: 10
Study 29535047 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype-guided opioid prescribing
Number of subjects: 0
Study 29535047 — intervention group
Group type: COMPARATOR
Intervention: Conventional pain management strategy
Number of subjects: 0
Study 27548212 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BTJ)
Number of subjects: 20
Study 27548212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 20
Study 24724616 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1800497 variant in women
Number of subjects: 25000
Study 24724616 — intervention group
Group type: COMPARATOR
Intervention: rs1800497 variant in men
Number of subjects: 25000
Study 24724616 — intervention group
Group type: EXPERIMENTAL
Intervention: rs6275 variant in women
Number of subjects: 25000
Study 24724616 — intervention group
Group type: COMPARATOR
Intervention: rs6275 variant in men
Number of subjects: 25000
Study 22012257 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 genotype
Number of subjects: 68
Study 22012257 — intervention group
Group type: EXPERIMENTAL
Intervention: ALDH3A1*2 genotype
Number of subjects: 68
Study 22012257 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTA1*B genotype
Number of subjects: 68
Study 19382614 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifen
Number of subjects: 0
Study 19382614 — intervention group
Group type: EXPERIMENTAL
Intervention: New SERMs (ospemifen, lasofoxifen, bazedoxifen, arzoxifen)
Number of subjects: 0
Study 19382614 — intervention group
Group type: EXPERIMENTAL
Intervention: SERM with parathormone or SERM with bisphosphonate
Number of subjects: 0
Study 19382614 — intervention group
Group type: COMPARATOR
Intervention: SERM with conventional hormonal replacement therapy
Number of subjects: 0
Study 17536191 — intervention group
Group type: EXPERIMENTAL
Intervention: High total dairy product consumption (4th quartile)
Number of subjects: 3627
Study 17536191 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing calcium intake
Number of subjects: 3627
Study 15464683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular Response Pacing (VRP) algorithm
Number of subjects: 0
Study 15464683 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 11430602 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day training course and resource pack for head and neck cancer nurses
Number of subjects: 8
Study 9251066 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg daily) with entacapone (200 mg)
Number of subjects: 13
Study 9251066 — intervention group
Group type: COMPARATOR
Intervention: Placebo with entacapone (200 mg)
Number of subjects: 13
Study 9251066 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 13
Study 9251066 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 13
Study 9251066 — intervention group
Group type: COMPARATOR
Intervention: Selegiline and Placebo
Number of subjects: 13
Study 8480959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 to 80 mg/d)
Number of subjects: 3390
Study 8480959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3390
Study 3816087 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing up
Number of subjects: 2
Study 3816087 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt (70 degrees)
Number of subjects: 2
Study 3816087 — intervention group
Group type: EXPERIMENTAL
Intervention: Active standing
Number of subjects: 2
Study 3816087 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural change
Number of subjects: 2
Study 29382673 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based care programme
Number of subjects: 433
Study 29382673 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 433
Study 25710083 — intervention group
Group type: EXPERIMENTAL
Intervention: NRP Cart
Number of subjects: 55
Study 25710083 — intervention group
Group type: COMPARATOR
Intervention: Generic storage drawer
Number of subjects: 55
Study 25063211 — intervention group
Group type: EXPERIMENTAL
Intervention: FBP0.9 (0.9 mGy, 120 kV)
Number of subjects: 29
Study 25063211 — intervention group
Group type: EXPERIMENTAL
Intervention: FBP0.5 (0.5 mGy, 100 kV)
Number of subjects: 29
Study 25063211 — intervention group
Group type: EXPERIMENTAL
Intervention: FBP0.2 (0.2 mGy, 80 kV)
Number of subjects: 29
Study 25063211 — intervention group
Group type: COMPARATOR
Intervention: SD-FBP (standard dose, 120 kV, 6 ± 1 mGy)
Number of subjects: 29
Study 23728281 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-team debriefing
Number of subjects: 120
Study 23728281 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led debriefing
Number of subjects: 120
Study 20525328 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved hand hygiene with guided hand-washing with soap and water
Number of subjects: 1050
Study 20525328 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved hand hygiene with alcohol-based hand rubbing disinfectant
Number of subjects: 1050
Study 20525328 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no change in hand hygiene practices)
Number of subjects: 1050
Study 18401652 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal explanation alone (group A)
Number of subjects: 37
Study 18401652 — intervention group
Group type: COMPARATOR
Intervention: Verbal explanation with request to sign a form (group B)
Number of subjects: 37
Study 18401652 — intervention group
Group type: COMPARATOR
Intervention: Staff members
Number of subjects: 37
Study 16796223 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil, 400 mg
Number of subjects: 54
Study 16796223 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine, 600 mg
Number of subjects: 54
Study 16796223 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine, 20 mg
Number of subjects: 54
Study 16796223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 14671195 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg exemestane daily for 10 days
Number of subjects: 12
Study 14671195 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg exemestane daily for 10 days
Number of subjects: 12
Study 14671195 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg exemestane (PK study)
Number of subjects: 12
Study 11261810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisone treatment
Number of subjects: 0
Study 11261810 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 8792690 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 MU of interferon-alpha 2b (IFN-alpha), three times weekly for 6 months (group A)
Number of subjects: 58
Study 8792690 — intervention group
Group type: COMPARATOR
Intervention: 3 MU of interferon-alpha 2b (IFN-alpha), three times weekly for 6 months (group B)
Number of subjects: 58
Study 8792690 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 MU of interferon-alpha 2b (IFN-alpha) (group A)
Number of subjects: 58
Study 8792690 — intervention group
Group type: COMPARATOR
Intervention: 3 MU of interferon-alpha 2b (IFN-alpha) (group B)
Number of subjects: 58
Study 8792690 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 58
Study 8792690 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced histological stage (severe fibrosis and cirrhosis)
Number of subjects: 58
Study 8792690 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of genotype 1
Number of subjects: 58
Study 7963722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent live oral rhesus rotavirus vaccine (RRV‐TV)
Number of subjects: 26
Study 3627885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee-for-service reimbursement
Number of subjects: 2
Study 28586534 — intervention group
Group type: EXPERIMENTAL
Intervention: tele‐IPT plus standard care
Number of subjects: 147
Study 28586534 — intervention group
Group type: COMPARATOR
Intervention: working alliance
Number of subjects: 147
Study 28586534 — intervention group
Group type: COMPARATOR
Intervention: goal and task working alliance subscales
Number of subjects: 147
Study 28586534 — intervention group
Group type: EXPERIMENTAL
Intervention: tele‐IPT
Number of subjects: 147
Study 27180442 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cream loaded with 2% Ananas comosus extract
Number of subjects: 11
Study 27180442 — intervention group
Group type: COMPARATOR
Intervention: Placebo control cream (no extract)
Number of subjects: 11
Study 25113138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (n=10 practices)
Number of subjects: 20
Study 25113138 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=10 practices)
Number of subjects: 20
Study 21710113 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic excision
Number of subjects: 21
Study 21710113 — intervention group
Group type: COMPARATOR
Intervention: Open excision
Number of subjects: 21
Study 19284125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (Voluven)
Number of subjects: 29
Study 19284125 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer solution
Number of subjects: 29
Study 17240222 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (800 microg)
Number of subjects: 652